{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:30:08Z","timestamp":1785389408213,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872263"],"award-info":[{"award-number":["81872263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioorg.2025.108878","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:55:55Z","timestamp":1755737755000},"page":"108878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pan-EGFR inhibitor targeting EGFR 19del, L858R\/T790M and C797S triple-mutations: Design, synthesis, and pharmacological evaluation"],"prefix":"10.1016","volume":"164","author":[{"given":"Luhong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108878_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108878_bb0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108878_bb0020","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bjc.6602793","article-title":"Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII","volume":"93","author":"Pedersen","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108878_bb0025","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","article-title":"Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells","volume":"13","author":"Li","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108878_bb0030","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108878_bb0035","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.3390\/cancers14205095","article-title":"Impact of T790M mutation status on later-line Osimertinib treatment in non-small cell lung Cancer patients","volume":"14","author":"Tang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108878_bb0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung Cancer to Gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108878_bb0045","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1158\/1078-0432.CCR-23-4035","article-title":"From rarity to reality: Osimertinib\u2019s promising horizon in treating uncommon EGFR mutations in non-small cell lung Cancer","volume":"30","author":"Fukuda","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108878_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116892","article-title":"The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells","volume":"176","author":"Kucinska","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108878_bb0055","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"lancet Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108878_bb0065","first-page":"1019","volume":"10","author":"Shi","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.bioorg.2025.108878_bb0070","doi-asserted-by":"crossref","first-page":"S1265","DOI":"10.1016\/j.jtho.2016.11.1787","article-title":"P3.02b-119 YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival over Osimertinib in animal model with brain metastases from NSCLC: topic: EGFR RES","volume":"12","author":"Hong","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0075","first-page":"504","article-title":"Adjuvant osimertinib improves overall survival","volume":"20","author":"Sidaway","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0080","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2023.11.016","article-title":"Allelic context of EGFR C797X\u2013mutant lung Cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes","volume":"19","author":"Lu","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other Osimertinib resistance mechanisms and clinical landscape of NSCLC post-Osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0090","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108878_bb0095","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108878_bb0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108878_bb0110","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"C. To","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108878_bb0115","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108878_bb0120","series-title":"Abstract 1320: Preclinical Evaluation of TQB3804, a Potent EGFR C797S Inhibitor, in: Proceedings: AACR Annual Meeting 2019; March 29\u2013April 3, 2019","author":"Liu","year":"2019"},{"key":"10.1016\/j.bioorg.2025.108878_bb0125","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose Furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study","volume":"20","author":"Chen","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108878_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107313","article-title":"The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistance","volume":"146","author":"Liu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117140","article-title":"Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance","volume":"283","author":"Patil","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41698-024-00542-9","article-title":"A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer","volume":"8","author":"Suzuki","year":"2024","journal-title":"Npj Precis. Onc."},{"key":"10.1016\/j.bioorg.2025.108878_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115671","article-title":"Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry","volume":"259","author":"Tang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117178","article-title":"From challenges to solutions: a review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer","volume":"284","author":"Ahmad","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0160","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1021\/acs.jcim.3c01636","article-title":"Binding thermodynamics of fourth-generation EGFR inhibitors revealed by absolute binding free energy calculations","volume":"63","author":"Zhou","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108878_bb0165","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1021\/acs.jmedchem.1c01055","article-title":"Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance","volume":"64","author":"Finlay","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0170","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity","volume":"16","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0175","doi-asserted-by":"crossref","first-page":"106618","DOI":"10.1016\/j.bioorg.2023.106618","article-title":"In-silico method for elucidation of prodigiosin as PARP-1 inhibitor a prime target of triple-negative breast cancer","volume":"138","author":"Sundararajan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0180","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes Osimertinib-resistant EGFR-19del\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108878_bb0185","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, ffexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.108878_bb0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.bioorg.2025.108878_bb0195","doi-asserted-by":"crossref","first-page":"8522","DOI":"10.3390\/ijms22168522","article-title":"EphB4 as a novel target for the EGFR-independent suppressive effects of Osimertinib on cell cycle progression in non-small cell lung Cancer","volume":"22","author":"Nanamiya","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108878_bb0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer."},{"key":"10.1016\/j.bioorg.2025.108878_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134499","article-title":"Structure-based modification of ortho-amidophenylaminopyrimidines as a novel mutant EGFR inhibitor against resistant non-small cell lung cancer","volume":"1274","author":"Wang","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108878_bb0210","first-page":"449","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities, expert Opin","volume":"10","author":"Genheden","year":"2015","journal-title":"Drug Dis."},{"key":"10.1016\/j.bioorg.2025.108878_bb0215","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2174\/1871520623666230223111217","article-title":"Osimertinib induces the opposite effect of proliferation and migration in the drug resistance of EGFR-T790M non-small cell lung Cancer cells","volume":"23","author":"Wang","year":"2023","journal-title":"Anti-Cancer Agent Me."},{"key":"10.1016\/j.bioorg.2025.108878_bb0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3892\/ijmm.2023.5305","article-title":"Characterization of circRNAs in established osimertinib-resistant non-small cell lung cancer cell lines","volume":"52","author":"Chen","year":"2023","journal-title":"Int. J. Mol. Med."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:26:51Z","timestamp":1762223211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825007588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"alternative-id":["S0045206825007588"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108878","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-EGFR inhibitor targeting EGFR 19del, L858R\/T790M and C797S triple-mutations: Design, synthesis, and pharmacological evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108878"}}